Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics is translating bestinclass gene editing technologies into lifesaving treatments and developing CAR Tcell immunotherapies for cancer
Raised
$172.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$142,000,000
Venture capital (Series C) - 2019
Aisling Capital Novartis Perceptive Advisors +6
$30,500,000
Venture capital (Series B) - 2018
Longitude Capital Vivo Capital Tavistock Group +1
Team Size
1–10
Employees
$30,500,000 Venture capital (Series B)
PE HUB , FinSMEs , Venture Funding News

Poseida Therapeutics snags $30.5 mln Series B

Messaging